W
AST

Wealthfront’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Wealthfront’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3
Closed – – 1610
2015
Q2 		$0 Buy
+3
New +$29 ﹤0.01% 1469

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Wealthfront's AST Position: Q3 2015 in Review

Wealthfront sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2015, closing a stake of 3 shares.

Wealthfront first reported a position in AST in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 58 funds tracked by Wall St. Rank hold AST as of Q3 2015.

  • Wealthfront reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2015 after selling out during the quarter.
  • Wealthfront sold 3 Asterias Biotherapeutics Inc. Series A shares in Q3 2015.
  • Wealthfront first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 1 quarter.
  • Wealthfront's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q2 2015.
  • 58 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2015.

Based on Wealthfront's 13F filing for Q3 2015, filed 18 Nov 2015.